No Result
View All Result
  • Private Data
  • Membership options
  • Login
  • COUNTRY
    • ITALY
    • IBERIA
    • FRANCE
    • UK&IRELAND
    • BENELUX
    • DACH
    • SCANDINAVIA&BALTICS
  • PRIVATE EQUITY
  • VENTURE CAPITAL
  • PRIVATE DEBT
  • DISTRESSED ASSETS
  • REAL ESTATE
  • FINTECH
  • GREEN
  • PREMIUM
    • ItaHubHOT
      • ItaHub Legal
      • ItaHub Tax
      • ItaHub Trend
    • REPORT
    • INSIGHT VIEW
    • Private Data
Subscribe
  • COUNTRY
    • ITALY
    • IBERIA
    • FRANCE
    • UK&IRELAND
    • BENELUX
    • DACH
    • SCANDINAVIA&BALTICS
  • PRIVATE EQUITY
  • VENTURE CAPITAL
  • PRIVATE DEBT
  • DISTRESSED ASSETS
  • REAL ESTATE
  • FINTECH
  • GREEN
  • PREMIUM
    • ItaHubHOT
      • ItaHub Legal
      • ItaHub Tax
      • ItaHub Trend
    • REPORT
    • INSIGHT VIEW
    • Private Data
Home PRIVATE EQUITY

Industry leading survey of Venture Capital (VC) life sciences investors of funds managing c.$300bn

Cisionby Cision
December 11, 2024
Reading Time: 4 mins read
in PRIVATE EQUITY, UK&IRELAND, VENTURE CAPITAL
Share on FacebookShare on Twitter

VCs favouring new investments over existing portfolio and have money to deploy
M&A expected to be strong
Top investor requirements – Team, Science and Differentiation

LONDON, Dec. 11, 2024 /PRNewswire/ — Optimum Strategic Communications (‘Optimum’), the international strategic life sciences communications firm, today announces the results of its Optimum European Life Sciences Investor Survey 2025: Great Expectations – Will 2025 Live Up to its Promise? The survey explored the current sentiment of leading VC firms collectively managing c.$300 billion in life science focused assets.

2024 has been another challenging year for fundraising in life sciences and, while the industry has not seen ‘across the board’ resurgence in confidence or capital flows, Optimum’s 2025 survey does present some grounds for optimism.

Key takeaways:

  • Investment criteria – The top three criteria investors are looking for when deciding to invest are: Great people, great science and differentiation.
  • Key drivers of investment – 86% believe that the availability of capital will be a key driver in financing activity over the next 12 months, given increased pressure to deploy large funds raised and the influence of public market performance on private valuations and funding rounds.
  • 57% of investors believe strong clinical data and promising innovation are the key drivers for investment, while 24% cited exits and returns as the most influential factors.
  • Fundraising outlook – 60% of investors are confident in the fundraising outlook for the next year and they believe that well-prepared companies with strong fundamentals can secure funding, albeit possibly at lower valuations than previously expected.
  • M&A – Investors believe there will continue to be strong M&A activity in 2025. Areas of focus are: cardiometabolic, immunology & inflammation, CNS and oncology.
  • Capital deployment – Compared to last year’s [2024] survey results, investors are no longer prioritising their existing portfolios, and the past year has seen a notable tilt towards new investments.
  • Appetite for obesity-related drugs has remained strong. Neurological and CNS disorders continue to attract attention, as recent data and new treatment mechanisms are bringing fresh investment opportunities.
  • Funding stage – 52% of investors believe that Series B will be the most active funding stage, with some noting an increase in crossovers, given the IPO backlog.

Commenting on the findings, Mary Clark, Chief Executive Officer of Optimum Strategic Communications, said: “While the past year has been challenging, there have been a number of recent large fundraisings which suggest that the industry has turned a corner. The feedback these investors have given offers companies a valuable blueprint on how to attract investment. For the right story, the money is there. But accessing capital continues to be very competitive, and telling a strong and compelling investment story remains vital.”

If you would like to receive the complete report, please email contact@optimumcomms.com or download it from our website here.

About Optimum Strategic Communications

Optimum Strategic Communications is an international strategic life sciences consultancy which specialises in investor relations, corporate and financial communications. Our senior team of healthcare specialists, based in London, Amsterdam, Stockholm, Zurich, San Francisco, San Diego and New York, are experienced and trusted advisors to some of the world’s most exciting public and private companies, both large and small, across pharmaceuticals, biotech, medtech, health tech, healthcare services and industrial biotechnology.

Over the last 25 years, our team has worked with over 400 healthcare companies, advising them on financial communications and investor relations, including major corporate activity such as fundraising, IPOs, M&A, as well as corporate reputation and crisis scenarios.

We have an exceptional network of contacts across the international investment community in Europe and the US; contacts we have built and maintained over the last three decades. The Optimum team includes ex-fund managers and analysts, as well as financial and corporate communications specialists.

For more information, please visit www.optimumcomms.com.

 

 

 

Cision View original content:https://www.prnewswire.co.uk/news-releases/industry-leading-survey-of-venture-capital-vc-life-sciences-investors-of-funds-managing-c300bn-302328853.html

Read the orginal article: undefined

Gateways to Italy

Gateways to Italy – Offer your services to funds and investors willing to explore opportunities in Italy. Become a partner!

Gateways to Italy – Offer your services to funds and investors willing to explore opportunities in Italy. Become a partner!

by Partner
June 6, 2023

Sign up to our newsletter

SIGN UP

Related Posts

REAL ESTATE

Is buying property still a good investment?

July 4, 2025
REAL ESTATE

Comings & Goings

July 4, 2025
REAL ESTATE

What is currently happening in the UK property market?

July 4, 2025

ItaHub

Crypto-assets supervision rules in Italy, Banca d’Italia will supervise payment systems and Consob on market abuse

Crypto-assets supervision rules in Italy, Banca d’Italia will supervise payment systems and Consob on market abuse

November 4, 2024
Italy’s SMEs export toward 260 bn euros in 2025

Italy’s SMEs export toward 260 bn euros in 2025

September 9, 2024
With two months to go before the NPL Directive, in Italy the securitization rebus is still to be unraveled

With two months to go before the NPL Directive, in Italy the securitization rebus is still to be unraveled

April 23, 2024
EU’s AI Act, like previous rules on technology,  looks more defensive than investment-oriented

EU’s AI Act, like previous rules on technology, looks more defensive than investment-oriented

January 9, 2024

Co-sponsor

Premium

Funds vying for management consulting firm BIP, a CVC portfolio company. All deals in the sector

Funds vying for management consulting firm BIP, a CVC portfolio company. All deals in the sector

March 6, 2025
Private equity, Italy 2024 closes with 588 deals as for investments and divestments from 549 in 2023. Here is the new BeBeez’s report

Private equity, Italy 2024 closes with 588 deals as for investments and divestments from 549 in 2023. Here is the new BeBeez’s report

February 10, 2025
Crypto-assets supervision rules in Italy, Banca d’Italia will supervise payment systems and Consob on market abuse

Crypto-assets supervision rules in Italy, Banca d’Italia will supervise payment systems and Consob on market abuse

November 4, 2024
Venture capital investments top €1.3bn in 208 rounds as of Sep30  in Italy. They were €1.5 in all 2023. The new BeBeez Report

Venture capital investments top €1.3bn in 208 rounds as of Sep30 in Italy. They were €1.5 in all 2023. The new BeBeez Report

October 28, 2024
Next Post

StorageMart Opens New Brighton Storage Facility, Blending Historic Restoration with Modern Innovation

Government as a key partner in innovation: Unlocking potential through public-private collaboration

EdiBeez srl

C.so Italia 22 - 20122 - Milano
C.F. | P.IVA 09375120962
Aut. Trib. Milano n. 102
del 3 aprile 2013

COUNTRY

Italy
Iberia
France
UK&Ireland
Benelux
DACH
Scandinavia&Baltics

CATEGORY

Private Equity
Venture Capital
Private Debt
Distressed Assets
Real Estate
Fintech
Green

PREMIUM

ItaHUB
Legal
Tax
Trend
Report
Insight view

WHO WE ARE

About Us
Media Partnerships
Contact

INFORMATION

Privacy Policy
Terms&Conditions
Cookie Police

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • COUNTRY
    • ITALY
    • IBERIA
    • FRANCE
    • UK&IRELAND
    • BENELUX
    • DACH
    • SCANDINAVIA&BALTICS
  • PRIVATE EQUITY
  • VENTURE CAPITAL
  • PRIVATE DEBT
  • DISTRESSED ASSETS
  • REAL ESTATE
  • FINTECH
  • GREEN
  • PREMIUM
    • ItaHub
      • ItaHub Legal
      • ItaHub Tax
      • ItaHub Trend
    • REPORT
    • INSIGHT VIEW
    • Private Data
Subscribe
  • Login
  • Cart